My Portfolio
+
LINK YOUR PORTFOLIO

Sangamo Therapeutics Inc SGMO:OTCQB

*Data is delayed | Exchange | USD
Last | 3:57 PM EDT
0.2162quote price arrow up+0.0022 (+1.028%)
Volume
2,108,758
52 week range
0.10 - 0.77
Loading...
  • Open0.22
  • Day High0.23
  • Day Low0.2141
  • Prev Close0.214
  • 52 Week High0.77
  • 52 Week High Date09/29/25
  • 52 Week Low0.10
  • 52 Week Low Date05/07/26

Latest On Sangamo Therapeutics Inc

 

Key Stats

  • Market Cap89.569M
  • Shares Out414.29M
  • 10 Day Average Volume15.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.29

Latest On Sangamo Therapeutics Inc

 

KEY STATS

  • Open0.22
  • Day High0.23
  • Day Low0.2141
  • Prev Close0.214
  • 52 Week High0.77
  • 52 Week High Date09/29/25
  • 52 Week Low0.10
  • 52 Week Low Date05/07/26
  • Market Cap89.569M
  • Shares Out414.29M
  • 10 Day Average Volume15.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.29

RATIOS/PROFITABILITY

  • EPS (TTM)-0.38
  • P/E (TTM)-0.56
  • Fwd P/E (NTM)-0.99
  • EBITDA (TTM)-106.662M
  • ROE (TTM)-2,891.84%
  • Revenue (TTM)34.557M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-356.89%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a...
H. Stewart Parker
Independent Chairman of the Board
Alexander Macrae Ph.D.
President, Chief Executive Officer, Director
Nikunj Jain
Interim Chief Financial Officer
Address
501 Canal Blvd.
Richmond, CA
94084
United States